Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
ASCLEPIuS trial: what clinicians have said so far
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
- NCT04194554 ↗
- Active, not recruiting
- University of Michigan Rogel Cancer Center
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ASCLEPIuS (niraparib plus abiraterone plus leuprolide in high-risk and node-positive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ASCLEPIuS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Niraparib; Leuprolide; Abiraterone Acetate; Stereotactic body radiotherapy (SBRT)
- Arms
- Niraparid Dose Escalation · Experimental
- Enrollment
- 102
- Primary outcomes
- Dose-limiting toxicities (Phase 1)
- Proportion of patients experiencing biochemical failure
- Sponsor
- University of Michigan Rogel Cancer Center with Janssen Scientific Affairs, LLC
- Start
- Nov 6, 2020
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04194554 · updated May 1, 2026